



HAL
open science

The follicular fluid metabolome differs according to the endometriosis phenotype

Khaled Pocate-Cheriet, Pietro Santulli, Fatiha Kateb, Mathilde Bourdon, Chloé Maignien, Frédéric Batteux, Sandrine Chouzenoux, Catherine Patrat, Jean Philippe Wolf, Gildas Bertho, et al.

► To cite this version:

Khaled Pocate-Cheriet, Pietro Santulli, Fatiha Kateb, Mathilde Bourdon, Chloé Maignien, et al.. The follicular fluid metabolome differs according to the endometriosis phenotype. *Reproductive BioMedicine Online*, 2020, 41, pp.1023 - 1037. 10.1016/j.rbmo.2020.09.002 . hal-03493619

HAL Id: hal-03493619

<https://hal.science/hal-03493619>

Submitted on 15 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **TITLE: THE FOLLICULAR FLUID METABOLOME DIFFERS ACCORDING TO THE**
2 **ENDOMETRIOSIS PHENOTYPE**

3

4 **AUTHOR NAMES AND AFFILIATIONS**

5

6 Pocate-Cheriet, K. 1, 2, 3, 6 *

7 Santulli, P. 1, 2, 4, 6 *

8 Kateb, F. 1, 2, 5 *

9 Bourdon, M. 1, 2, 4, 6

10 Maignien, C. 1, 2, 4

11 Batteux, F. 1, 2, 6, 7

12 Chouzenoux, S. 1, 2, 6

13 Patrat, C. 1, 2, 3

14 Wolf, J.P. 1, 2, 3 †

15 Bertho, G. 1, 2, 5 †

16 Chapron, C. 1, 2, 4, 6 †

17

18 ¹ Université de Paris, Faculté de Médecine. Paris, France

19 ² Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin (HUPC), Centre
20 Hospitalier Paris Centre, France

21 ³ Service d'Histologie-Embryologie-Biologie de la Reproduction, Paris, France

22 ⁴ Département de Gynécologie Obstétrique II et Médecine de la Reproduction, Paris,
23 France

47 **ABSTRACT**

48 **Research Question:** Is there a follicular fluid (FF)-specific metabolic profile in deep
49 infiltrating endometriosis (DIE) according to the presence of an associated ovarian
50 endometrioma (OMA) that could lead to the identification of biomarkers for diagnosis
51 and prognosis of the disease?

52 **Design:** A prospective cohort study. Proton-nuclear magnetic resonance (¹H-NMR)
53 experiments were carried out on 50 FF samples from patients presenting with DIE,
54 associated or not with an OMA, and on 29 FF samples from patients with infertility
55 due to a tubal obstruction. The follicles were aspirated individually.

56 **Results:** FF glucose levels were decreased in patients with DIE compared with the
57 controls, whereas the levels of lactate and pyruvate were increased. FF samples
58 from patients with DIE also had higher levels of lipids and ketone bodies. Conversely,
59 the levels of citrate, creatine, and amino acids such as tyrosine and alanine were
60 decreased in FF samples from patients with DIE. When taking into account the
61 presence of an associated OMA in patients with DIE, the metabolic analysis revealed
62 enhanced levels of glycerol and ketone bodies in patients with OMA, indicative of the
63 activation of lipolysis followed by β -oxidation. Conversely, the levels of lactate and
64 pyruvate were increased in patients without OMA, whereas the level of glucose was
65 decreased, highlighting the activation of the anaerobic glycolysis pathway.
66 Differences in the levels of amino acids such as threonine and glutamine were also
67 statistically relevant to discriminate between the presence or absence of OMA.

68 **Conclusions:** These results are indicative of a mitochondrial dysregulation in
69 endometriosis phenotypes, with a modified balance between anaerobic glycolysis
70 and β -oxidation in OMA phenotypes that could potentially affect the fertility of patients
71 with endometriosis. Since FF composition has been shown to be correlated with both

72 oocyte development and the implantation outcome after fertilization, these findings
73 may help explain the high level of infertility observed in these patients.

74

75 **KEYWORDS:**

76 Endometriosis; Metabolomics; Follicular fluid; Endometrioma; Deep infiltrating
77 endometriosis

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97 INTRODUCTION

98

99 Endometriosis is a gynecological disease characterized by ectopic growth of
100 endometrial cells outside the uterine cavity (Sampson, 1927), leading to an estrogen-
101 dependent chronic inflammation environment that can cause pelvic pain and infertility
102 (Chapron *et al.*, 2019). Endometriosis affects 10% to 15% of women of reproductive
103 age, approximately 40% of whom are infertile (de Ziegler *et al.*, 2010). Different
104 phenotypes of this disease have been described, including superficial endometriosis
105 (SUP), deep infiltrating endometriosis (DIE), and ovarian endometrioma (OMA); the
106 latter is considered to be the most severe form and it has a detrimental impact on
107 ovarian physiology. The occurrence of infertility can be explained by the presence of
108 chronic inflammation and oxidative stress in the pelvic cavity (Santulli *et al.*, 2015).
109 Others have pointed out the negative impact of the disease on oocyte quality, which
110 can cause embryonic development impairment and result in a lower implantation
111 competence (Sanchez *et al.*, 2014). Currently, the main selection criteria for oocytes
112 and embryos for in vitro fertilization (IVF) rely on morphological aspects associated
113 with cleavage kinetics; however, these criteria have limited predictive capability
114 (Bromer and Seli, 2008). The development of new, non-invasive, and effective
115 methods to select the embryos most likely to give rise to a favourable pregnancy
116 outcome, therefore, represents a high-priority objective in this field.

117 Metabolomics, defined as the simultaneous detection and quantification of a large
118 number of low-molecular-weight molecules in different biological matrices, is a
119 powerful method that can be used to study an organism's state; either during normal
120 conditions or in response to perturbations such as environmental factors, drugs, or
121 disease. Various metabolomic techniques have been developed, including mass

122 spectrometry (MS) and proton–nuclear magnetic resonance (¹H-NMR) spectroscopy
123 (Amberg *et al.*, 2017; Markley *et al.*, 2017). The latter technique has the advantage
124 that it does not result in destruction of the samples, and it can provide a quantitative
125 evaluation with minimal handling (Duarte and Gil, 2012). In recent years,
126 metabolomics has increasingly been used as an approach to gain a better
127 understanding of various pathophysiological mechanisms involved in the onset of
128 diseases.

129 In the context of infertility, follicular fluid (FF) is one of the most relevant fluids for
130 analysis (Bender *et al.*, 2010). Indeed, FF, originating both from plasma and local
131 secretion by cumulus cells, has been shown to be essential for oocyte development
132 (Da Broi *et al.*, 2018; Dumesic *et al.*, 2015; Edwards, 1974; Fortune, 1994).
133 Determination of its composition may, therefore, allow identification of biomarkers
134 associated with oocyte quality (Revelli *et al.*, 2009). In case of endometriosis, for
135 which a lower oocyte quality has been observed (Garrido *et al.*, 2000; Xu *et al.*, 2015;
136 Orazov *et al.*, 2019), determination of the composition of FF could provide insights
137 into the metabolic pathways involved in the disease and that potentially influence
138 oocyte growth and quality. This could lead to the identification of new biomarkers
139 (Sutton *et al.*, 2003; Wallace *et al.*, 2012). From this perspective, and considering
140 that the composition of the FF surrounding each oocyte is unique, it is imperative to
141 study the FF of every single follicle.

142 Few metabolomics studies have focused on the characteristics of FF of patients with
143 endometriosis (Cordeiro *et al.*, 2017, 2015; Karaer *et al.*, 2019; Marianna *et al.*, 2017;
144 Sun *et al.*, 2018 Morelli *et al.*, 2019). Indeed, only two studies to date have analyzed
145 the FF of a single follicle, and these involved only a small number of samples and did
146 not take into account the severity of the disease (Karaer *et al.*, 2019; Morelli *et al.*,

147 2019). These authors highlighted the importance of the anaerobic glycolysis
148 pathway, with increased lactate and pyruvate levels observed in the FF of patients
149 with endometriosis. This is in keeping with previous work carried out using pooled FF
150 samples (Marianna *et al.*, 2017). Other metabolites, such as ketone bodies (KB), also
151 appeared to be particularly relevant for the characterization of endometriosis (Morelli
152 *et al.*, 2019)._Given that endometriosis is a heterogeneous condition that probably
153 has variable effects on FF composition, it is crucial to take into account the
154 endometriosis phenotype when evaluating its impact.

155 In this context, the aim of this study was to evaluate the impact of DIE on FF
156 composition, using ¹H-NMR-based metabolomics, based on analysis of FF from
157 single oocytes following controlled ovarian stimulation, and to evaluate whether the
158 presence or absence of an OMA affects the FF composition.

159

160 **MATERIALS AND METHODS**

161

162 **Patients**

163 The study population comprised sixteen women who were infertile and who were
164 prospectively enrolled in an assisted reproductive technology (ART) attempt at our
165 center between March and June 2018. The women were divided into two groups (an
166 endometriosis group and a control group).

167 The endometriosis group comprised nine women presenting with DIE, some with and
168 some without an OMA. The study data were stored in a prospectively managed
169 database and subsequently used for the analysis. Each patient's personal history
170 was obtained during a face-to-face interview, supplemented by items recorded using
171 a structured questionnaire (Chapron *et al.*, 2010b). The data items collected included

172 (Chapron *et al.*, 2010a) age, parity, gravidity, height, weight, body mass index (BMI),
173 existence and duration of infertility, lifestyle habits, history of hormonal and/or
174 surgical treatments for symptomatic endometriosis, and the existence of
175 gynecological pain symptoms (dysmenorrhea, deep dyspareunia, non-cyclic chronic
176 pelvic pain (NCCPP)), and gastrointestinal and lower urinary tract symptoms. All of
177 the women with endometriosis underwent an appropriate pre-ART imaging workup to
178 obtain a clear diagnosis and staging of the disease. For the DIE and OMA
179 phenotypes, previously published imaging criteria using transvaginal ultrasound
180 (TVUS), magnetic resonance imaging (MRI), or transrectal ultrasonography
181 (Guerriero *et al.*, 2016; Guerriero *et al.*, 2018; Nisenblat *et al.*, 2016; Van den Bosch
182 and Van Schoubroeck, 2018).

183 The control group comprised seven women for whom the infertility was due to a tubal
184 obstruction only, with no other associated pathological context, such as inflammation
185 or infection. Both groups were not associated with any male infertility factors, and all
186 of the semen parameters were normal according to the World Health Organization
187 (WHO) criteria (WHO, 2010). Women who were more than 42 years of age, exhibited
188 a chronic viral infection, or who had already been included in another ART research
189 protocol were excluded from the study.

190 All of the enrolled patients provided written informed consent and the study was
191 approved by the relevant Ethical Committee, “Comité de Protection des Personnes”
192 (CPP-2017-32), and registered at Clinicaltrials.gov (EndOvo, NCT03241329).

193

194 **Controlled ovarian stimulation protocol**

195 The following controlled ovarian stimulation (COS) protocols were performed
196 according to our institutional clinical protocols, using 150–450 IU/day of recombinant

197 follicle-stimulating hormone (rFSH) (Puregon, MSD, Courbevoie, France; Gonal-F,
198 Merck-Serono, Lyon, France) and human menopausal gonadotropin (hMG)
199 (Menopur, Ferring Pharmaceuticals, Gentilly, France) (Bourdon *et al.*, 2017). Final
200 oocyte maturation was triggered when ≥ 3 ovarian follicles with a diameter of ≥ 17
201 mm were visible by ultrasound and when the estradiol (E2) levels were ≥ 1.000
202 pg/mL. Final oocyte maturation was achieved using either a single injection of 0.2 mg
203 gonadotropin-releasing hormone (GnRH) agonist (Triptoreline, Decapeptyl, Ibsen
204 France) or 250 μg of recombinant human chorionic gonadotropin (rhCG) (Ovitrelle,
205 Serono, France). Oocyte retrieval was performed 35 to 36 hours later by transvaginal
206 aspiration under ultrasound guidance.

207

208 **Collection and processing of FF samples**

209 The main objective during the ovarian collection was that the entire content of each
210 follicle was aspirated individually into a single dry sterile tube pre-heated to 37 °C
211 while avoiding any blood contamination. After each follicle aspiration, the puncture
212 syringe and the tubing were washed before the next follicle was processed in the
213 same way. Only FF containing a single oocyte were retained for the study; FF that
214 did not contain an oocyte or that contained more than one oocyte were excluded
215 from the study. FF samples that were free of blood contamination were centrifuged at
216 300 x g for 10 min and the supernatants were aliquoted and stored at -80 °C until they
217 were analyzed.

218 The samples were not randomized during the collection but were instead collected as
219 groups and not at the same time of day. All of the included patients had fasted before
220 the oocyte collection took place under local or general anesthesia.

221

222 **Sample preparation**

223 The samples were randomly mixed prior to the NMR measurements, with the aim of
224 mixing the running order of the two groups and thus avoid systematic error
225 measurements. The ^1H -NMR experiments were carried out using whole samples
226 without any extraction. Prior to the NMR measurements, the FF samples were
227 thawed on ice. For each NMR sample, 500 μL of FF was added to 50 μL of a solution
228 containing 1 mM sodium trimethylsilylpropionate salt (TSP), which was used as the
229 ^1H -NMR chemical shift reference of -0.016 ppm, dissolved in D_2O , used as a field-
230 frequency lock. A total volume of 550 μL was then transferred into 5-mm NMR tubes
231 for analysis.

232

233 **Spectral acquisition and processing**

234 The ^1H -NMR spectra were obtained with a 500 MHz Bruker Avance spectrometer
235 equipped with a 5-mm $^1\text{H}/^{13}\text{C}$ dual cryoprobe using a SampleXpressTM automated
236 sample changer. A Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence (Meiboom
237 and Gill, 1958) with a spin-echo delay of 400 μs was used to remove any broad
238 peaks originating from macromolecules. For each experiment, after a delay of 5 min
239 for temperature equilibration at 300 K, a total of 512 scans were acquired with 32 768
240 points and an acquisition time of 1.6 s. A recycle delay of 2 s and a chemical shift
241 spectral window of 20.65 ppm were used, resulting in a total experiment time of 33
242 min. The ^1H -NMR spectra were processed using Topspin 3.1 software (Bruker,
243 GMBH, Karlsruhe, Germany). A zero-filling to 65 536 points with an exponential
244 anodization function using a line broadening of 0.3 Hz was applied prior to Fourier
245 transformation. The spectra were then manually phased and baseline corrected. The
246 spectra were aligned before bucketing, and ultimately the alanine methyl group signal

247 was used as a chemical shift reference at 1.47 ppm, instead of the TSP signal, which
248 is known to vary in the presence of proteins or lipoproteins. Each metabolite was
249 assigned using Chenomx NMR suite 7.1 software (Chenomx Inc., Edmonton,
250 Canada), the human metabolome database (HMDB) (Wishart *et al.*, 2007), and
251 previously published data (Piñero-Sagredo *et al.*, 2010).

252 Spectral bucketing was carried out using the variable size bucketing (VSB) method,
253 as implemented in NMRProcFlow (Jacob *et al.*, 2017). This method allows the
254 spectra to be manually divided into unevenly spaced buckets of different sizes to
255 avoid peaks lying in different consecutive integration regions. Only spectral regions
256 corresponding to metabolite signals were included in the analysis. A total of 215
257 buckets was obtained and further integrated to build the matrix of variables used in
258 the statistical analysis. This matrix of variables was pretreated using MetaboAnalyst
259 (Chong *et al.*, 2018; Xia *et al.*, 2009) before performing the statistical analysis.
260 Constant sum normalization (CSN) was first applied to account for any differences in
261 sample concentration. Finally, Pareto scaling (Eriksson *et al.*, 2004) was used to
262 avoid enhancing background noise and to reduce the importance of large fold
263 changes compared to small ones, while staying closer to the original data (van den
264 Berg *et al.*, 2006).

265

266 **Statistical analysis**

267 All of the clinical data were compiled in a computerized database and analyzed using
268 IBM® SPSS® Statistics version 23.0 software (SPSS Inc. Headquarters, USA). We
269 used the Mann–Whitney U test for the quantitative variables and Fisher’s exact test
270 or Pearson’s chi-square test for the qualitative variables, as appropriate. A p-value
271 < 0.05 was considered to be statistically significant.

272 Conventional metabolomics analysis, comprising both univariate and multivariate
273 analysis, was carried out to identify metabolites statistically relevant for discriminating
274 between the groups being studied. Univariate analysis, which deals with each
275 variable one at a time, was performed using the Student's *t*-test for comparisons
276 between two groups, and one-way ANOVA was used for comparisons among more
277 than two groups, using MetaboAnalyst (Chong *et al.*, 2018; Xia *et al.*, 2009).
278 Metabolites were considered statistically relevant when their p-value was < 0.05.
279 Multivariate analysis, which considers all variables simultaneously, was performed
280 using SIMCA software (Sartorius Stedim Biotech). Both principal component analysis
281 (PCA) and supervised orthogonal projections to latent structures discriminant
282 analysis (OPLS-DA) (Trygg and Wold, 2002) were carried out. The latter, taking into
283 account the class of the different samples, was used to maximize class
284 discrimination. The quality of the models thus obtained was assessed according to
285 the usual quality factors, i.e., the cumulative explained variance of observed data X,
286 R^2X ; the cumulative explained variance of group assignment Y, R^2Y ; and the
287 estimate of predictive ability, Q^2 . The goodness of fit of the models was further
288 evaluated using CV-ANOVA (Eriksson *et al.*, 2008), with a p-value < 0.05 considered
289 to be statistically significant. Variables responsible for the class discrimination in the
290 OPLS-DA models were identified with the variable importance on projection (VIP)
291 values. The VIP values correspond to the variable weights in the discrimination
292 observed in the model. A VIP score threshold of 1 was used in our study to consider
293 the variables relevant in the group separation. Important metabolites for the
294 classification model were further identified using the S-line plot generated from
295 SIMCA (Figure A in the Supplementary files). The S-line plot is a spectra-like plot
296 colored according to the correlation coefficient ($p(\text{corr})$) between each variable and

297 the classification score of the OPLS-DA model (right vertical axis). The more it tends
298 to the red, the more important the metabolite is for separation of the two groups in
299 the corresponding model. It also allows visualization of the covariance (p(ctr))
300 between each variable and the classification score of the OPLS-DA model, although
301 it is less interpretable since its magnitude is scale-dependent and affected by the
302 intensity of the signal according to the noise level. Important metabolites for the
303 discrimination between the two groups should have a clear covariance as well as a
304 high absolute value of the correlation coefficient.

305

306 **RESULTS**

307

308 **Study population**

309 Nine women with DIE and seven control patients with a tubal obstruction were
310 included in our study, resulting in a total of 50 and 29 FF samples, respectively. Of
311 the nine patients with DIE, five had an associated OMA, corresponding to 25
312 samples. The patients' characteristics are presented in Table 1. No significant
313 differences were noted in terms of age, BMI, parity, gravidity, type and length of
314 infertility, or ovarian reserve. The follicular volume and the total retrieved oocytes
315 were also similar in both groups. When taking into account the endometriosis group,
316 the baseline characteristics of the OMA+ and the OMA- DIE patients were also
317 similar, and there were no significant differences between them (Table 2).

318

319 **Follicular fluid profiles of patients with DIE compared with controls**

320 An untargeted ¹H-NMR-based metabolomics approach was used to obtain an overall
321 profile of the FF composition in patients with DIE and in control patients. This

322 procedure allows identification of metabolites present at different levels in the two
323 groups, with no prior knowledge of those that are potentially relevant. Figure 1 shows
324 a typical ¹H-NMR spectrum of FF from a patient with DIE, with the assignment of the
325 most relevant metabolites indicated above their corresponding peaks. These
326 metabolite peaks corresponded to glucose, pyruvate, lactate, lipids, and ketone
327 bodies (KB), and they were statistically relevant for discriminating between the DIE
328 and the control group in the univariate analysis. The Student's *t*-test results indicated
329 that the glucose levels were significantly lower in the patients with DIE compared with
330 the glucose levels in the control patients, whereas the levels of lactate and pyruvate
331 were increased (Figure 2A). The FF of the patients with DIE also had higher levels of
332 lipids and KB, i.e., acetoacetate, 3-hydroxybutyrate, and acetone, as well as
333 threonine (Figure 2B). Conversely, the levels of citrate, creatine, and amino acids
334 such as tyrosine and alanine were lower in the FF of patients with DIE (Figure 2C).
335 Supervised multivariate analysis led to a clear separation between the two groups, as
336 demonstrated by the OPLS-DA score plot shown in Figure 3A. The quality of the
337 corresponding model was validated through the high-quality factors obtained,
338 $R^2X = 0.839$, $R^2Y = 0.844$, and $Q^2 = 0.697$, as well as the *p*-value (6.93×10^{-13})
339 obtained from the CV-ANOVA analysis of the model. The variables responsible for
340 discrimination between the two groups were plotted as a VIP score plot, shown in
341 Figure 3B, and sorted according to their weight in the model. The corresponding
342 most relevant metabolites were the same as those obtained in the univariate
343 analysis, further confirming their importance for discriminating between the FF
344 composition in patients with and without DIE.
345

346 **Follicular fluid profiles of patients with DIE as a function of the presence or**
347 **absence of OMA**

348 Interestingly, the OPLS-DA score plot presented in Figure 3A also showed two
349 clusters within the endometriosis group, which corresponded to the presence (OMA+)
350 or the absence (OMA-) of endometrioma. We, therefore, decided to look at
351 differences in FF composition according to the endometriosis phenotypes, since each
352 analysis from the OMA+ and the OMA- DIE patients was made between them. The
353 difference between the OMA+ and the OMA- DIE patients was first assessed by
354 univariate analysis, which revealed the importance of several metabolites for
355 discriminating between the two groups. Among these metabolites, KB and glycerol
356 were present at increased levels in the OMA+ patients (Figure 4A). Conversely, the
357 levels of lactate and pyruvate were increased in the OMA- patients, whereas the level
358 of glucose was decreased (Figure 4B). Some amino acids were also statistically
359 relevant for discriminating between the two groups, with isoleucine levels being
360 increased and alanine, glutamine, and tyrosine levels markedly decreased in the
361 OMA+ phenotype. Interestingly, high levels of threonine and glutamine were
362 biomarkers of the OMA- phenotype. The levels of succinate were also higher in the
363 OMA+ patients. Finally, the creatine and succinate levels were decreased in the
364 OMA- patients (Figure 4C). The OPLS-DA score plot revealed a clear separation
365 between the three groups (Figure 5), the model being validated with a p-
366 value = 1.9×10^{-14} , obtained from a CV-ANOVA analysis.

367

368 **DISCUSSION**

369

370 Our study confirms the difference in FF composition between patients with
371 endometriosis and control patients, while also showing that there is a specific
372 metabolic signature according to the endometriosis phenotype. We found that the
373 glucidic balance in the FF of women with endometriosis differed from that in the
374 women in the control group, with a decrease in glucose levels and an increase in
375 pyruvate and lactate levels observed in the FF of patients with endometriosis. A
376 lower concentration of several amino acids was also noted in the presence of the
377 disease. Concurrently, we found that the concentrations of KB and free fatty acids
378 (FFA) were higher in the FF of women with endometriosis. Finally, and for the first
379 time, we showed that the FF of patients with OMA also exhibited specific metabolic
380 profiles when compared with the profiles of endometriosis patients without OMA.

381 Using a non-targeted ¹H-NMR metabolomics approach, the present study highlighted
382 the importance of energetic pathways in the characterization of FF of patients with
383 endometriosis. Indeed, the FF samples from these patients exhibited a decrease in
384 glucose levels, whereas the levels of lactate and pyruvate were increased. These
385 three metabolites are associated with glycolysis, which has been shown to provide a
386 source of energy for oocyte growth (Boland *et al.*, 1994; Piñero-Sagredo *et al.*, 2010).
387 Thus, it appears that this pathway is more active in endometriosis patients.
388 Endometriotic cells are characterized by higher energy needs and they display
389 properties comparable to those of cancer cells (Maignien *et al.*, 2019; Wingfield *et al.*,
390 1995), and the enhanced level of glycolysis could hence arise from the well-known
391 Warburg effect (Warburg, 1956), thereby allowing for rapid cell proliferation.

392 These observations are in agreement with the decreased alanine levels seen in the
393 FF from patients with endometriosis, which is consistent with other studies (Marianna
394 *et al.*, 2017). Alanine can be converted into pyruvate, thereby shifting the anaerobic

395 glycolysis pathway toward lactate production. The decreased level of alanine is,
396 therefore, consistent with an increased level of both pyruvate and lactate. Since
397 alanine has been shown to increase meiotic maturation, the level at which it is
398 present could be important for oocyte development (Cetica *et al.* 2007). To provide a
399 better understanding of how these metabolic changes are interconnected, the
400 pathways potentially affected by endometriosis are presented schematically in Figure
401 6.

402 Enhanced glycolysis could also be due to an increase in granulosa cell (GC) activity
403 as a response to the increased need for energy in the rather low oxygen environment
404 in patients with endometriosis (Gull *et al.*, 1999; Redding *et al.*, 2008; Sutton *et al.*,
405 2003). On the other hand, the accumulation of lactate and pyruvate could also reflect
406 the dysfunction of cellular respiration in mitochondria, as has been observed in
407 endometriosis tissue (Atkins *et al.*, 2019). This is supported by the observation of
408 higher levels of threonine (Noster *et al.*, 2019) in endometriosis FF samples, which
409 probably reflects an accumulation of this essential amino acid that may no longer be
410 able to enter the tricarboxylic acid (TCA) cycle. Citrate, which is an intermediate in
411 the TCA cycle, is present at a decreased level in endometriosis FF, further
412 supporting this hypothesis.

413 The reduced activity of mitochondrial respiration in endometriosis could potentially
414 arise from the hypoxic conditions observed during the establishment of the disease
415 (Hsiao *et al.*, 2015), or from defective mitochondria (Hsu *et al.*, 2015; Atkins *et al.*,
416 2019; Xu *et al.*, 2015). Oxidative stress (OS) can also have a deleterious effect on
417 mitochondrial function (Wang *et al.*, 2013), while reactive oxygen species (ROS) may
418 exert a negative feedback effect on the TCA cycle. Since endometriosis is associated
419 with OS (Donnez *et al.*, 2016; Jana *et al.*, 2013; Ngô *et al.*, 2009; Santulli *et al.*, 2015;

420 Scutiero *et al.*, 2017), which has also been shown to affect the composition of
421 endometriosis FF (Regiani *et al.*, 2015; Sanchez *et al.*, 2017; Scutiero *et al.*, 2017),
422 the metabolic switch to anaerobic glycolysis observed in endometriosis could be
423 linked to enhanced OS. This is in agreement with previous observations of
424 endometriosis serum samples (Jana *et al.*, 2013).

425 We also observed a higher level of KB and FFA in patients with endometriosis. The
426 main KB production pathway, mediated by the action of lipases, is activated when
427 glucose levels are not sufficient to meet the energy needs of cells. KB are indeed the
428 final products of lipid metabolism, via their degradation into FFA, followed by β -
429 oxidation leading to acetyl-CoA, which is one of the substrates of the TCA cycle. If
430 the amount of acetyl-CoA is too high, or if the TCA cycle is dysfunctional, acetyl-CoA
431 is diverted to the formation of KB (Dhillon and Gupta, 2020; Fukao *et al.*, 2004;
432 Kerner and Hoppel, 2004; Owen and Hanson, 2004). Conversion of tyrosine into
433 acetoacetate could also contribute to KB production (Knox, 1955; Knox and LeMay-
434 Knox, 1951), which is consistent with the lower level of tyrosine observed in FF
435 samples of patients with DIE. However, in a non-pathological situation, KB are mainly
436 produced in the mitochondria of liver cells and certain other cells, e.g., human
437 astrocytes (Guzmán and Blázquez, 2004; Le Foll and Levin, 2016). The presence of
438 KB in the FF, therefore, raises an intriguing question. Either these compounds can be
439 produced locally in the FF, or they come from blood exchange in patients.
440 Interestingly, we recently reported an abnormally high level of KB in the blood of
441 patients with endometriosis (Maignien *et al.*, 2020). It is also interesting to note that
442 some cancer cells have the remarkable ability to adapt their metabolism to produce
443 KB (Martinez-Outschoorn *et al.*, 2012). Therefore, it can be hypothesized that
444 endometrial cells are similarly capable of producing KB. In addition to their role as

445 energy-rich compounds, KB have been shown to play a role in promoting
446 inflammation (Chriett *et al.*, 2019; Kurepa *et al.*, 2012; Shi *et al.*, 2014) as well as OS
447 (Cheng *et al.*, 2019; Kanikarla-Marie and Jain, 2015; Shi *et al.*, 2016), so it is perhaps
448 not surprising that their levels can increase during endometriosis, consistent with the
449 inflammatory and oxidative character of this disease. Interestingly, citrate, the
450 metabolism of which is also associated with oxygen radical production and
451 inflammation (Convertini *et al.*, 2016; O'Neill, 2011; Williams and O'Neill, 2018), also
452 exhibited a statistically lower level in endometriosis FF, thus suggesting enhanced
453 cytosolic degradation in patients with endometriosis.

454 Finally, we also noted a lower level of creatine in endometriosis FF. Creatine is the
455 result of an alternative lipid metabolic pathway via choline. Its lower level could
456 support the shift of lipid metabolism toward β -oxidation; although it could also
457 indicate a higher degree of conversion into phosphocreatine, which is considered to
458 be an energy reserve. Taken together, these results support the hypothesis of a
459 decrease in mitochondrial respiration in endometriosis in favor of other energetic
460 pathways, such as anaerobic glycolysis and lipid metabolism (Figure 6).

461

462 **OMA presence (OMA+) vs OMA absence (OMA-) in patients with DIE**

463 Interestingly, the multivariate analysis carried out on the results of FF samples from
464 the patients with DIE and the control group highlighted the presence of two clusters
465 in the endometriosis group, corresponding to the presence or absence of OMA.
466 Given that the presence of an associated OMA is a marker for the severity of DIE
467 (Chapron *et al.*, 2009), we observed a linear variation in the levels of a number of
468 molecular entities that corresponded to the seriousness of the disease, thus
469 suggesting that these metabolites could potentially be used as biomarkers in FF. The

470 levels of KB increased monotonically, thus implying an increased predilection
471 towards β -oxidation as an energetic pathway in OMA+. The increased level of
472 glycerol (released during lipid metabolism) is in keeping with this hypothesis. We
473 support the notion that in the presence of OMA, the high energy requirements of
474 highly proliferative endometriotic cells preferentially activate the KB production
475 pathway. This could be explained by the higher levels of estradiol seen in patients
476 with OMA (Huhtinen *et al.*, 2012), which has been shown to stimulate the activity of
477 lipases (Cox & York *et al.*, 2017; Palin *et al.*, 2003). On the other hand, the OMA- FF
478 samples had lower levels of glucose and higher levels of lactate and pyruvate, which
479 could either arise from blood circulation or from local secretion and metabolic
480 processes_ (Gosden *et al.*, 1988), thus suggesting that OMA- relies on anaerobic
481 glycolysis, which may reflect a less functional TCA cycle in OMA- patients. This is
482 further supported by the finding that levels of succinate, an intermediate in the TCA
483 cycle, are decreased, whereas threonine, which would no longer be able to enter the
484 TCA cycle, accumulates more in OMA- than in OMA+ patients.

485 The increased level of creatine in the OMA+ patients compared with its level in the
486 OMA- patients could arise from a higher rate of conversion of phosphocreatine into
487 creatine through the action of creatine kinases (CK), thereby fulfilling the high energy
488 needs of endometrioma cells. This could be seen as a parallel with certain invasive
489 cancer cells, in association with increased CK activity (Zarghami *et al.*, 1996). CK
490 activity also depends on E2 levels (Fournier *et al.*, 1996); these have been shown to
491 be higher in ovarian endometriosis cases (Huhtinen *et al.*, 2012), which is consistent
492 with the higher level of creatine observed in OMA+ patients.

493 Interestingly, glutamine levels appeared to be lower in OMA+ compared with the
494 levels in OMA- patients. Glutamine metabolism is known to support inflammation

495 (Calder and Yaqoob, 1999) as well as rapid cell proliferation in cancer (Hosios *et al.*,
496 2016; Yuan *et al.*, 2015), and could be activated by a high estrogen concentration
497 (Zhou *et al.*, 2019). The glutamine level is thus expected to decrease in the presence
498 of an OMA, which is also associated with a high concentration of inflammatory
499 molecules (Ohata *et al.*, 2008; Sanchez *et al.*, 2014). Altogether, these data suggest
500 different energetic pathways are in use according to the DIE phenotype. Whereas
501 DIE without OMA appears to mainly rely on glycolysis, DIE in the presence of OMA
502 appears to rely on other energetic pathways, such as the KB and glutamine
503 metabolism pathways, in a similar way to cancer cells.

504

505 **Strengths and limitations of the study**

506 The main strengths of this study lie in the novelty of the subject and the
507 methodological design: (i) To the best of our knowledge, this is the first study to focus
508 on the effect of endometriosis on FF composition using a relatively high number of
509 samples obtained single follicular aspirations, with each FF sample having its own
510 oocyte. Only two studies with a similar design have been performed to date, and they
511 used fewer samples, with only one to three follicles individually aspirated (Karaer *et al.*,
512 2019; Morelli *et al.*, 2019), whereas we analyzed 79 samples. (ii) To the best of
513 our knowledge, this is the first study reporting a difference in FF composition
514 according to the precise endometriosis phenotype, i.e., DIE with the presence or
515 absence of associated OMA. (iii) Only patients who had undergone a thorough
516 imaging exploration of their pelvic cavity were included, and thus their endometriosis
517 status was assessed with a high degree of precision according to strict, previously
518 published imaging criteria (Guerriero *et al.*, 2016; Guerriero *et al.*, 2018; Nisenblat *et al.*,
519 2016; Van den Bosch and Van Schoubroeck, 2018). Given the heterogeneous

520 nature of the disease, we selected patients with well-defined phenotypes and we
521 used the surgical classification (SUP, OMA, or DIE), which describes the
522 endometriosis phenotype more accurately than the rAFS classification (the rAFS can
523 include different types of endometriotic lesions at the same stage, including SUP,
524 OMA, and DIE) (Chapron *et al.*, 2019). (iv) Finally, we employed statistical analyses
525 using an untargeted approach, measuring and comparing many metabolite signals
526 simultaneously, to identify those involved in the disease, with no prior knowledge of
527 which might be relevant.

528 However, our study has some limitations, the main one being the fact that the
529 patients with endometriosis included in our evaluation had the most severe form of
530 the disease. This is due to the specific nature of the patients encountered in our
531 institution, which is a reference center for endometriosis. As endometriosis is a
532 heterogeneous condition, its effect on FF composition may differ according to the
533 condition's degree of severity. We also acknowledge that there is no ideal control
534 group for studying FF metabolic profiles in women with endometriosis (Zondervan *et*
535 *al.*, 2002). An ideal control group would consist of women who were not infertile and
536 who lacked any other gynecological conditions. Our control group comprised women
537 who underwent ART for tubal obstruction. These women could hypothetically also
538 exhibit altered FF metabolomic profiles, for unknown reasons. In this context, any
539 associations could hence have been underestimated.

540

541 **CONCLUSIONS**

542

543 The effect of endometriosis on FF was well documented, as was the characterization
544 of biomarkers that can be used to discriminate between the different phenotypes.

545 These biomarkers are mainly involved in different energetic pathways and they could
546 reflect a mitochondrial dysfunction in endometriosis that may potentially affect the
547 fertility of patients with endometriosis (Xu *et al.*, 2015). Interestingly, different
548 energetic pathways are activated according to the endometriosis phenotype. The
549 absence of endometrioma appears to result in a reliance on glycolysis, whereas the
550 presence of endometrioma results in a reliance on lipid and glutamine metabolism as
551 an energy supply, in a very similar way to cancer cells.

552 Since FF composition has been shown to be correlated with both oocyte
553 development and the implantation outcome after fertilization (O’Gorman *et al.*, 2013;
554 Wallace *et al.*, 2012), these findings may help explain the high level of infertility
555 observed in these patients.

556 However, a further step remains, namely to correlate these results with oocyte
557 quality, embryo quality, and development, which would then represent a new tool for
558 predicting the chance of a pregnancy with a favorable outcome.

559

560 **Authors’ roles**

561 K.P.C. designed the study, interpreted the data, wrote and revised the manuscript,
562 and approved the final draft. P.S. designed the study, analyzed and interpreted the
563 data, revised the manuscript, and approved the final draft. F.K. analyzed and
564 interpreted the data, wrote and revised the manuscript, and approved the final draft.
565 M.B., C.M., F.B., S.C., and C.P. interpreted the data and reviewed the manuscript.
566 J.P.W., G.B., and C.C. designed the study, revised the manuscript, and approved the
567 final draft.

568

569 **Acknowledgments**

570 The authors thank all of the team members of the biological and clinical IVF Unit of
571 the Cochon-Port Royal University Hospital center for the assistance that they
572 provided. The authors also gratefully acknowledge Prof. Didier Borderie for his help
573 with biochemistry.

574

575 **Funding**

576 This study was partially supported by a Merck Biopharma France Research Grant
577 awarded to C.C. and P.S. The funder played no role in the study design, data
578 collection and analysis, decision to publish, or preparation of the manuscript. There
579 was no additional external funding received for this study.

580

581 **Conflict of interest**

582 None to declare

583 **BIBLIOGRAPHY**

584

585 Amberg, A., Riefke, B., Schlotterbeck, G., Ross, A., Senn, H., Dieterle, F., Keck, M., 2017.
586 NMR and MS Methods for Metabolomics. *Methods Mol. Biol.* Clifton NJ 1641, 229–258.

587 https://doi.org/10.1007/978-1-4939-7172-5_13

588 Atkins, H.M., Bharadwaj, M.S., O'Brien Cox, A., Furdui, C.M., Appt, S.E., Caudell, D.L.,
589 2019. Endometrium and endometriosis tissue mitochondrial energy metabolism in a
590 nonhuman primate model. *Reprod. Biol. Endocrinol.* 17, 70. [https://doi.org/10.1186/s12958-](https://doi.org/10.1186/s12958-019-0513-8)
591 [019-0513-8](https://doi.org/10.1186/s12958-019-0513-8)

592 Bender, K., Walsh, S., Evans, A.C.O., Fair, T., Brennan, L., 2010. Metabolite concentrations
593 in follicular fluid may explain differences in fertility between heifers and lactating cows.
594 *Reproduction* 139, 1047–1055. <https://doi.org/10.1530/REP-10-0068>

595 Boland, N.I., Humpherson, P.G., Leese, H.J., Gosden, R.G., 1994. The effect of glucose
596 metabolism on murine follicle development and steroidogenesis in vitro. *Hum. Reprod.* 9,
597 617–623. <https://doi.org/10.1093/oxfordjournals.humrep.a138559>

598 Bourdon, M., Santulli, P., Gayet, V., Maignien, C., Marcellin, L., Pocate-Cheriet, K.,
599 Chapron, C., 2017. Assisted reproduction technique outcomes for fresh versus deferred
600 cryopreserved day-2 embryo transfer: a retrospective matched cohort study. *Reprod. Biomed.*
601 *Online* 34, 248–257. <https://doi.org/10.1016/j.rbmo.2016.11.015>

602 Bromer, J.G., Seli, E., 2008. Assessment of embryo viability in assisted reproductive
603 technology: shortcomings of current approaches and the emerging role of metabolomics.

604 *Curr. Opin. Obstet. Gynecol.* 20, 234–241. <https://doi.org/10.1097/GCO.0b013e3282fe723d>

605 Calder, P.C., Yaqoob, P., 1999. Glutamine and the immune system. *Amino Acids* 17, 227–
606 241. <https://doi.org/10.1007/BF01366922>

607 Chapron, C., Bourret, A., Chopin, N., Dousset, B., Leconte, M., Amsellem-Ouazana, D., de
608 Ziegler, D., Borghese, B., 2010a. Surgery for bladder endometriosis: long-term results and
609 concomitant management of associated posterior deep lesions. *Hum. Reprod. Oxf. Engl.* 25,
610 884–889. <https://doi.org/10.1093/humrep/deq017>
611 Chapron, C., Chopin, N., Borghese, B., Foulot, H., Dousset, B., Vacher-Lavenu, M.C., Vieira,
612 M., Hasan, W., Bricou, A., 2006. Deeply infiltrating endometriosis: pathogenetic implications
613 of the anatomical distribution. *Hum. Reprod. Oxf. Engl.* 21, 1839–1845.
614 <https://doi.org/10.1093/humrep/del079>
615 Chapron, C., Marcellin, L., Borghese, B., Santulli, P., 2019. Rethinking mechanisms,
616 diagnosis and management of endometriosis. *Nat. Rev. Endocrinol.* 15, 666–682.
617 <https://doi.org/10.1038/s41574-019-0245-z>
618 Chapron, C., Pietin-Vialle, C., Borghese, B., Davy, C., Foulot, H., Chopin, N., 2009.
619 Associated ovarian endometrioma is a marker for greater severity of deeply infiltrating
620 endometriosis. *Fertil. Steril.* 92, 453–457. <https://doi.org/10.1016/j.fertnstert.2008.06.003>
621 Chapron, C., Souza, C., de Ziegler, D., Lafay-Pillet, M.-C., Ngô, C., Bijaoui, G., Goffinet, F.,
622 Borghese, B., 2010b. Smoking habits of 411 women with histologically proven endometriosis
623 and 567 unaffected women. *Fertil. Steril.* 94, 2353–2355.
624 <https://doi.org/10.1016/j.fertnstert.2010.04.020>
625 Cheng, X., Yang, S., Xu, C., Li, L., Zhang, Y., Guo, Y., Zhang, C., Li, P., Long, M., He, J.,
626 2019. Proanthocyanidins Protect against β -Hydroxybutyrate-Induced Oxidative Damage in
627 Bovine Endometrial Cells. *Molecules* 24. <https://doi.org/10.3390/molecules24030400>
628 Chong, J., Soufan, O., Li, C., Caraus, I., Li, S., Bourque, G., Wishart, D.S., Xia, J., 2018.
629 MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. *Nucleic*
630 *Acids Res.* 46, W486–W494. <https://doi.org/10.1093/nar/gky310>
631 Chriett, S., Dąbek, A., Wojtala, M., Vidal, H., Balcerczyk, A., Pirola, L., 2019. Prominent
632 action of butyrate over β -hydroxybutyrate as histone deacetylase inhibitor, transcriptional
633 modulator and anti-inflammatory molecule. *Sci. Rep.* 9, 742. [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-018-36941-9)
634 [018-36941-9](https://doi.org/10.1038/s41598-018-36941-9)
635 Convertini, P., Menga, A., Andria, G., Scala, I., Santarsiero, A., Morelli, M.A.C., Iacobazzi,
636 V., Infantino, V., 2016. The contribution of the citrate pathway to oxidative stress in Down
637 syndrome. *Immunology* 149, 423–431. <https://doi.org/10.1111/imm.12659>
638 Cordeiro, F.B., Cataldi, T.R., Perkel, K.J., Teixeira da Costa, L. do V., Rochetti, R.C.,
639 Stevanato, J., Eberlin, M.N., Zylbersztejn, D.S., Cedenho, A.P., Lo Turco, E.G., 2015.
640 Lipidomics analysis of follicular fluid by ESI-MS reveals potential biomarkers for ovarian
641 endometriosis. *J. Assist. Reprod. Genet.* 32, 1817–1825. [https://doi.org/10.1007/s10815-015-](https://doi.org/10.1007/s10815-015-0592-1)
642 [0592-1](https://doi.org/10.1007/s10815-015-0592-1)
643 Cordeiro, F.B., Cataldi, T.R., Teixeira da Costa, L. do V., de Souza, B.Z., Montani, D.A.,
644 Fraietta, R., Labate, C.A., Cedenho, A.P., Lo Turco, E.G., 2017. Metabolomic profiling in
645 follicular fluid of patients with infertility-related deep endometriosis. *Metabolomics* 13, 120.
646 <https://doi.org/10.1007/s11306-017-1262-3>
647 Cox-York, K.A., Erickson, C.B., Pereira, R.I., Bessesen, D.H., Van Pelt, R.E., 2017. Region-
648 specific effects of oestradiol on adipose-derived stem cell differentiation in post-menopausal
649 women. *J. Cell. Mol. Med.* 21, 677–684. <https://doi.org/10.1111/jcmm.13011>
650 Da Broi, M.G., Giorgi, V.S.I., Wang, F., Keefe, D.L., Albertini, D., Navarro, P.A., 2018.
651 Influence of follicular fluid and cumulus cells on oocyte quality: clinical implications. *J.*
652 *Assist. Reprod. Genet.* 35, 735–751. <https://doi.org/10.1007/s10815-018-1143-3>
653 de Ziegler, D., Gayet, V., Aubriot, F.X., Fauque, P., Streuli, I., Wolf, J.P., de Mouzon, J.,
654 Chapron, C., 2010. Use of oral contraceptives in women with endometriosis before assisted
655 reproduction treatment improves outcomes. *Fertil. Steril.* 94, 2796–2799.
656 <https://doi.org/10.1016/j.fertnstert.2010.05.056>

657 Dhillon, K.K., Gupta, S., 2020. Biochemistry, Ketogenesis, in: StatPearls. StatPearls
658 Publishing, Treasure Island (FL).

659 Donnez, J., Binda, M.M., Donnez, O., Dolmans, M.-M., 2016. Oxidative stress in the pelvic
660 cavity and its role in the pathogenesis of endometriosis. *Fertil. Steril.* 106, 1011–1017.
661 <https://doi.org/10.1016/j.fertnstert.2016.07.1075>

662 Duarte, I.F., Gil, A.M., 2012. Metabolic signatures of cancer unveiled by NMR spectroscopy
663 of human biofluids. *Prog. Nucl. Magn. Reson. Spectrosc.* 62, 51–74.
664 <https://doi.org/10.1016/j.pnmrs.2011.11.002>

665 Dumesic, D.A., Meldrum, D.R., Katz-Jaffe, M.G., Krisher, R.L., Schoolcraft, W.B., 2015.
666 Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health. *Fertil.*
667 *Steril.* 103, 303–316. <https://doi.org/10.1016/j.fertnstert.2014.11.015>

668 Edwards, R.G., 1974. FOLLICULAR FLUID. *Reproduction* 37, 189–219.
669 <https://doi.org/10.1530/jrf.0.0370189>

670 Eriksson, L., Antti, H., Gottfries, J., Holmes, E., Johansson, E., Lindgren, F., Long, I.,
671 Lundstedt, T., Trygg, J., Wold, S., 2004. Using chemometrics for navigating in the large data
672 sets of genomics, proteomics, and metabonomics (gpm). *Anal. Bioanal. Chem.* 380, 419–429.
673 <https://doi.org/10.1007/s00216-004-2783-y>

674 Eriksson, L., Trygg, J., Wold, S., 2008. CV-ANOVA for significance testing of PLS and
675 OPLS® models. *J. Chemom.* 22, 594–600. <https://doi.org/10.1002/cem.1187>

676 Fortune, J.E., 1994. Ovarian follicular growth and development in mammals. *Biol. Reprod.*
677 50, 225–232. <https://doi.org/10.1095/biolreprod50.2.225>

678 Fournier, B., Häring, S., Kaye, A.M., Sömjen, D., 1996. Stimulation of creatine kinase
679 specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens
680 and its modulation by calciotropic hormones. *J. Endocrinol.* 150, 275–285.
681 <https://doi.org/10.1677/joe.0.1500275>

682 Fukao, T., Lopaschuk, G.D., Mitchell, G.A., 2004. Pathways and control of ketone body
683 metabolism: on the fringe of lipid biochemistry. *Prostaglandins Leukot. Essent. Fatty Acids*
684 70, 243–251. <https://doi.org/10.1016/j.plefa.2003.11.001>

685 Garrido, N., Navarro, J., Remohí, J., Simón, C., Pellicer, A., 2000. Follicular hormonal
686 environment and embryo quality in women with endometriosis. *Hum. Reprod. Update* 6, 67–
687 74. <https://doi.org/10.1093/humupd/6.1.67>

688 Gosden, R.G., Hunter, R.H., Telfer, E., Torrance, C., Brown, N., 1988. Physiological factors
689 underlying the formation of ovarian follicular fluid. *J. Reprod. Fertil.* 82, 813–825.
690 <https://doi.org/10.1530/jrf.0.0820813>

691 Guerriero, Stefano, Alcázar, J.L., Pascual, M.A., Ajossa, S., Perniciano, M., Piras, A., Mais,
692 V., Piras, B., Schirru, F., Benedetto, M.G., Saba, L., 2018. Deep Infiltrating Endometriosis:
693 Comparison Between 2-Dimensional Ultrasonography (US), 3-Dimensional US, and
694 Magnetic Resonance Imaging. *J. Ultrasound Med. Off. J. Am. Inst. Ultrasound Med.* 37,
695 1511–1521. <https://doi.org/10.1002/jum.14496>

696 Guerriero, S., Condous, G., van den Bosch, T., Valentin, L., Leone, F.P.G., Van Schoubroeck,
697 D., Exacoustos, C., Installé, A.J.F., Martins, W.P., Abrao, M.S., Hudelist, G., Bazot, M.,
698 Alcazar, J.L., Gonçalves, M.O., Pascual, M.A., Ajossa, S., Savelli, L., Dunham, R., Reid, S.,
699 Menakaya, U., Bourne, T., Ferrero, S., Leon, M., Bignardi, T., Holland, T., Jurkovic, D.,
700 Benacerraf, B., Osuga, Y., Somigliana, E., Timmerman, D., 2016. Systematic approach to
701 sonographic evaluation of the pelvis in women with suspected endometriosis, including terms,
702 definitions and measurements: a consensus opinion from the International Deep
703 Endometriosis Analysis (IDEA) group. *Ultrasound Obstet. Gynecol. Off. J. Int. Soc.*
704 *Ultrasound Obstet. Gynecol.* 48, 318–332. <https://doi.org/10.1002/uog.15955>

705 Guerriero, S., Saba, L., Pascual, M.A., Ajossa, S., Rodriguez, I., Mais, V., Alcazar, J.L., 2018.
706 Transvaginal ultrasound vs magnetic resonance imaging for diagnosing deep infiltrating

707 endometriosis: systematic review and meta-analysis. *Ultrasound Obstet. Gynecol. Off. J. Int.*
708 *Soc. Ultrasound Obstet. Gynecol.* 51, 586–595. <https://doi.org/10.1002/uog.18961>

709 Gull, I., Geva, E., Lerner-Geva, L., Lessing, J.B., Wolman, I., Amit, A., 1999. Anaerobic
710 glycolysis. The metabolism of the preovulatory human oocyte. *Eur. J. Obstet. Gynecol.*
711 *Reprod. Biol.* 85, 225–228. [https://doi.org/10.1016/s0301-2115\(99\)00012-3](https://doi.org/10.1016/s0301-2115(99)00012-3)

712 Guzmán, M., Blázquez, C., 2004. Ketone body synthesis in the brain: possible
713 neuroprotective effects. *Prostaglandins Leukot. Essent. Fatty Acids* 70, 287–292.
714 <https://doi.org/10.1016/j.plefa.2003.05.001>

715 Hosios, A.M., Hecht, V.C., Danai, L.V., Johnson, M.O., Rathmell, J.C., Steinhäuser, M.L.,
716 Manalis, S.R., Vander Heiden, M.G., 2016. Amino Acids Rather than Glucose Account for
717 the Majority of Cell Mass in Proliferating Mammalian Cells. *Dev. Cell* 36, 540–549.
718 <https://doi.org/10.1016/j.devcel.2016.02.012>

719 Hsiao, K.-Y., Lin, S.-C., Wu, M.-H., Tsai, S.-J., 2015. Pathological functions of hypoxia in
720 endometriosis. *Front. Biosci. Elite Ed.* 7, 309–321.

721 Hsu, A.L., Townsend, P.M., Oehninger, S., Castora, F.J., 2015. Endometriosis may be
722 associated with mitochondrial dysfunction in cumulus cells from subjects undergoing in vitro
723 fertilization-intracytoplasmic sperm injection, as reflected by decreased adenosine
724 triphosphate production. *Fertil. Steril.* 103, 347–352.e1.
725 <https://doi.org/10.1016/j.fertnstert.2014.11.002>

726 Huhtinen, K., Desai, R., Stähle, M., Salminen, A., Handelsman, D.J., Perheentupa, A.,
727 Poutanen, M., 2012. Endometrial and Endometriotic Concentrations of Estrone and Estradiol
728 Are Determined by Local Metabolism Rather than Circulating Levels. *J. Clin. Endocrinol.*
729 *Metab.* 97, 4228–4235. <https://doi.org/10.1210/jc.2012-1154>

730 Jacob, D., Deborde, C., Lefebvre, M., Maucourt, M., Moing, A., 2017. NMRProcFlow: a
731 graphical and interactive tool dedicated to 1D spectra processing for NMR-based
732 metabolomics. *Metabolomics* 13, 36. <https://doi.org/10.1007/s11306-017-1178-y>

733 Jana, S.K., Dutta, M., Joshi, M., Srivastava, S., Chakravarty, B., Chaudhury, K., 2013. 1H
734 NMR based targeted metabolite profiling for understanding the complex relationship
735 connecting oxidative stress with endometriosis. *BioMed Res. Int.* 2013, 329058.
736 <https://doi.org/10.1155/2013/329058>

737 Kanikarla-Marie, P., Jain, S.K., 2015. Role of Hyperketonemia in Inducing Oxidative Stress
738 and Cellular Damage in Cultured Hepatocytes and Type 1 Diabetic Rat Liver. *Cell. Physiol.*
739 *Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* 37, 2160–2170.
740 <https://doi.org/10.1159/000438573>

741 Karaer, A., Tuncay, G., Mumcu, A., Dogan, B., 2019. Metabolomics analysis of follicular
742 fluid in women with ovarian endometriosis undergoing in vitro fertilization. *Syst. Biol.*
743 *Reprod. Med.* 65, 39–47. <https://doi.org/10.1080/19396368.2018.1478469>

744 Kerner, J., Hoppel, C.L., 2004. Ketogenesis, in: Lennarz, W.J., Lane, M.D. (Eds.),
745 *Encyclopedia of Biological Chemistry*. Elsevier, New York, pp. 505–507.
746 <https://doi.org/10.1016/B0-12-443710-9/00346-X>

747 Knox, W.E., 1955. [38] Enzymes involved in conversion of tyrosine to acetoacetate: A. l-
748 Tyrosine-Oxidizing system of liver, in: *Methods in Enzymology*. Academic Press, pp. 287–300.
749 [https://doi.org/10.1016/S0076-6879\(55\)02202-7](https://doi.org/10.1016/S0076-6879(55)02202-7)

750 Knox, W.E., LeMay-Knox, M., 1951. The oxidation in liver of l-tyrosine to acetoacetate
751 through p-hydroxyphenylpyruvate and homogentisic acid. *Biochem. J.* 49, 686–693.

752 Kurepa, D., Pramanik, A.K., Kakkilaya, V., Caldito, G., Groome, L.J., Bocchini, J.A., Jain,
753 S.K., 2012. Elevated acetoacetate and monocyte chemotactic protein-1 levels in cord blood of
754 infants of diabetic mothers. *Neonatology* 102, 163–168. <https://doi.org/10.1159/000339286>

755 Le Foll, C., Levin, B.E., 2016. Fatty acid-induced astrocyte ketone production and the control
756 of food intake. *Am. J. Physiol. - Regul. Integr. Comp. Physiol.* 310, R1186–R1192.

757 <https://doi.org/10.1152/ajpregu.00113.2016>
758 Maignien, C., Santulli, P., Chouzenoux, S., Gonzalez-Foruria, I., Marcellin, L., Doridot, L.,
759 Jeljeli, M., Grange, P., Reis, F.M., Chapron, C., Batteux, F., 2019. Reduced alpha-2,6
760 sialylation regulates cell migration in endometriosis. *Hum. Reprod.* 34, 479–490.
761 <https://doi.org/10.1093/humrep/dey391>
762 Marianna, S., Alessia, P., Susan, C., Francesca, Caprio, Angela, S., Francesca, Capone,
763 Antonella, N., Patrizia, I., Nicola, C., Emilio, C., 2017. Metabolomic profiling and
764 biochemical evaluation of the follicular fluid of endometriosis patients. *Mol. Biosyst.* 13,
765 1213–1222. <https://doi.org/10.1039/c7mb00181a>
766 Markley, J.L., Brüschweiler, R., Edison, A.S., Eghbalnia, H.R., Powers, R., Raftery, D.,
767 Wishart, D.S., 2017. The future of NMR-based metabolomics. *Curr. Opin. Biotechnol.*,
768 *Analytical biotechnology* 43, 34–40. <https://doi.org/10.1016/j.copbio.2016.08.001>
769 Martinez-Outschoorn, U.E., Lin, Z., Whitaker-Menezes, D., Howell, A., Lisanti, M.P., Sotgia,
770 F., 2012. Ketone bodies and two-compartment tumor metabolism: stromal ketone production
771 fuels mitochondrial biogenesis in epithelial cancer cells. *Cell Cycle Georget. Tex* 11, 3956–
772 3963. <https://doi.org/10.4161/cc.22136>
773 MEIBOOM, S., GILL, D., 1958. MODIFIED SPIN-ECHO METHOD FOR MEASURING
774 NUCLEAR RELAXATION TIMES. *Rev. Sci. Instrum.* 29, 688–691.
775 <https://doi.org/10.1063/1.1716296>
776 Morelli, M.A.C., Iuliano, A., Schettini, S.C.A., Petruzzi, D., Ferri, A., Colucci, P., Viggiani,
777 L., CuvIELLO, F., Ostuni, A., 2019. NMR metabolic profiling of follicular fluid for
778 investigating the different causes of female infertility: a pilot study. *Metabolomics* 15, 19.
779 <https://doi.org/10.1007/s11306-019-1481-x>
780 Ngô, C., Chéreau, C., Nicco, C., Weill, B., Chapron, C., Batteux, F., 2009. Reactive oxygen
781 species controls endometriosis progression. *Am. J. Pathol.* 175, 225–234.
782 <https://doi.org/10.2353/ajpath.2009.080804>
783 Nisenblat, V., Bossuyt, P.M.M., Farquhar, C., Johnson, N., Hull, M.L., 2016. Imaging
784 modalities for the non-invasive diagnosis of endometriosis. *Cochrane Database Syst. Rev.* 2,
785 CD009591. <https://doi.org/10.1002/14651858.CD009591.pub2>
786 Noster, J., Persicke, M., Chao, T.-C., Krone, L., Heppner, B., Hensel, M., Hansmeier, N.,
787 2019. Impact of ROS-Induced Damage of TCA Cycle Enzymes on Metabolism and Virulence
788 of *Salmonella enterica* serovar Typhimurium. *Front. Microbiol.* 10.
789 <https://doi.org/10.3389/fmicb.2019.00762>
790 O’Gorman, A., Wallace, M., Cottell, E., Gibney, M.J., McAuliffe, F.M., Wingfield, M.,
791 Brennan, L., 2013. Metabolic profiling of human follicular fluid identifies potential
792 biomarkers of oocyte developmental competence. *Reproduction* 146, 389–395.
793 <https://doi.org/10.1530/REP-13-0184>
794 Ohata, Y., Harada, T., Miyakoda, H., Taniguchi, F., Iwabe, T., Terakawa, N., 2008. Serum
795 interleukin-8 levels are elevated in patients with ovarian endometrioma. *Fertil. Steril.* 90,
796 994–999. <https://doi.org/10.1016/j.fertnstert.2007.07.1355>
797 O’Neill, L.A.J., 2011. A critical role for citrate metabolism in LPS signalling. *Biochem. J.*
798 438, e5–6. <https://doi.org/10.1042/BJ20111386>
799 Orazov, M., Yevseyevich, R., Isaakovich, I., Хамошина, М., Borisovna, S., 2019. Oocyte
800 quality in women with infertility associated endometriosis. *Gynecol. Endocrinol.* 35, 24–26.
801 <https://doi.org/10.1080/09513590.2019.1632088>
802 Owen, O.E., Hanson, R.W., 2004. Ketone Bodies, in: Martini, L. (Ed.), *Encyclopedia of*
803 *Endocrine Diseases*. Elsevier, New York, pp. 125–136. <https://doi.org/10.1016/B0-12-475570-4/01447-5>
804
805 Palin, S.L., McTernan, P.G., Anderson, L.A., Sturdee, D.W., Barnett, A.H., Kumar, S., 2003.
806 17Beta-estradiol and anti-estrogen ICI:compound 182,780 regulate expression of lipoprotein

807 lipase and hormone-sensitive lipase in isolated subcutaneous abdominal adipocytes.
808 *Metabolism*. 52, 383–388. <https://doi.org/10.1053/meta.2003.50088>
809 Piñero-Sagredo, E., Nunes, S., de Los Santos, M.J., Celda, B., Esteve, V., 2010. NMR
810 metabolic profile of human follicular fluid. *NMR Biomed*. 23, 485–495.
811 <https://doi.org/10.1002/nbm.1488>
812 Redding, G.P., Bronlund, J.E., Hart, A.L., 2008. Theoretical investigation into the dissolved
813 oxygen levels in follicular fluid of the developing human follicle using mathematical
814 modelling. *Reprod. Fertil. Dev.* 20, 408–417. <https://doi.org/10.1071/rd07190>
815 Regiani, T., Cordeiro, F.B., da Costa, L. do V.T., Salgueiro, J., Cardozo, K., Carvalho, V.M.,
816 Perkel, K.J., Zylbersztejn, D.S., Cedenho, A.P., Lo Turco, E.G., 2015. Follicular fluid
817 alterations in endometriosis: label-free proteomics by MS(E) as a functional tool for
818 endometriosis. *Syst. Biol. Reprod. Med.* 61, 263–276.
819 <https://doi.org/10.3109/19396368.2015.1037025>
820 Revelli, A., Piane, L.D., Casano, S., Molinari, E., Massobrio, M., Rinaudo, P., 2009.
821 Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics.
822 *Reprod. Biol. Endocrinol. RBE* 7, 40. <https://doi.org/10.1186/1477-7827-7-40>
823 Sampson, J., 1927. Peritoneal endometriosis due to menstrual dissemination of endometrial
824 tissue into the peritoneal cavity. *Am J Obstet Gynecol* 442–69.
825 Sanchez, A.M., Vanni, V.S., Bartiromo, L., Papaleo, E., Zilberberg, E., Candiani, M.,
826 Orvieto, R., Viganò, P., 2017. Is the oocyte quality affected by endometriosis? A review of
827 the literature. *J. Ovarian Res.* 10. <https://doi.org/10.1186/s13048-017-0341-4>
828 Sanchez, A.M., Viganò, P., Somigliana, E., Panina-Bordignon, P., Vercellini, P., Candiani,
829 M., 2014. The distinguishing cellular and molecular features of the endometriotic ovarian
830 cyst: from pathophysiology to the potential endometrioma-mediated damage to the ovary.
831 *Hum. Reprod. Update* 20, 217–230. <https://doi.org/10.1093/humupd/dmt053>
832 Santulli, P., Chouzenoux, S., Fiorese, M., Marcellin, L., Lemarechal, H., Millischer, A.-E.,
833 Batteux, F., Borderie, D., Chapron, C., 2015. Protein oxidative stress markers in peritoneal
834 fluids of women with deep infiltrating endometriosis are increased. *Hum. Reprod.* 30, 49–60.
835 <https://doi.org/10.1093/humrep/deu290>
836 Scutiero, G., Iannone, P., Bernardi, G., Bonaccorsi, G., Spadaro, S., Volta, C.A., Greco, P.,
837 Nappi, L., 2017. Oxidative Stress and Endometriosis: A Systematic Review of the Literature.
838 *Oxid. Med. Cell. Longev.* 2017. <https://doi.org/10.1155/2017/7265238>
839 Shi, X., Li, D., Deng, Q., Peng, Z., Zhao, C., Li, Xiaobing, Wang, Z., Li, Xinwei, Liu, G.,
840 2016. Acetoacetic acid induces oxidative stress to inhibit the assembly of very low density
841 lipoprotein in bovine hepatocytes. *J. Dairy Res.* 83, 442–446.
842 <https://doi.org/10.1017/S0022029916000546>
843 Shi, X., Li, X., Li, D., Li, Y., Song, Y., Deng, Q., Wang, J., Zhang, Y., Ding, H., Yin, L.,
844 Zhang, Y., Wang, Z., Li, X., Liu, G., 2014. β -Hydroxybutyrate Activates the NF- κ B
845 Signaling Pathway to Promote the Expression of Pro-Inflammatory Factors in Calf
846 Hepatocytes. *Cell. Physiol. Biochem.* 33, 920–932. <https://doi.org/10.1159/000358664>
847 Sutton, M.L., Gilchrist, R.B., Thompson, J.G., 2003. Effects of in-vivo and in-vitro
848 environments on the metabolism of the cumulus–oocyte complex and its influence on oocyte
849 developmental capacity. *Hum. Reprod. Update* 9, 35–48.
850 <https://doi.org/10.1093/humupd/dmg009>
851 Trygg, J., Wold, S., 2002. Orthogonal projections to latent structures (O-PLS). *J. Chemom.*
852 16, 119–128. <https://doi.org/10.1002/cem.695>
853 van den Berg, R.A., Hoefsloot, H.C., Westerhuis, J.A., Smilde, A.K., van der Werf, M.J.,
854 2006. Centering, scaling, and transformations: improving the biological information content
855 of metabolomics data. *BMC Genomics* 7, 142. <https://doi.org/10.1186/1471-2164-7-142>
856 Van den Bosch, T., Van Schoubroeck, D., 2018. Ultrasound diagnosis of endometriosis and

857 adenomyosis: State of the art. *Best Pract. Res. Clin. Obstet. Gynaecol.* 51, 16–24.
858 <https://doi.org/10.1016/j.bpobgyn.2018.01.013>
859 Wallace, M., Cottell, E., Gibney, M.J., McAuliffe, F.M., Wingfield, M., Brennan, L., 2012.
860 An investigation into the relationship between the metabolic profile of follicular fluid, oocyte
861 developmental potential, and implantation outcome. *Fertil. Steril.* 97, 1078-1084.e8.
862 <https://doi.org/10.1016/j.fertnstert.2012.01.122>
863 Wang, C.-H., Wu, S.-B., Wu, Y.-T., Wei, Y.-H., 2013. Oxidative stress response elicited by
864 mitochondrial dysfunction: implication in the pathophysiology of aging. *Exp. Biol. Med.*
865 Maywood NJ 238, 450–460. <https://doi.org/10.1177/1535370213493069>
866 Warburg, O., 1956. On the Origin of Cancer Cells. *Science* 123, 309–314.
867 Williams, N.C., O’Neill, L.A.J., 2018. A Role for the Krebs Cycle Intermediate Citrate in
868 Metabolic Reprogramming in Innate Immunity and Inflammation. *Front. Immunol.* 9.
869 <https://doi.org/10.3389/fimmu.2018.00141>
870 Wingfield, M., Macpherson, A., Healy, D.L., Rogers, P.A.W., 1995. Cell proliferation is
871 increased in the endometrium of women with endometriosis *. *Fertil. Steril.* 64, 340–346.
872 [https://doi.org/10.1016/S0015-0282\(16\)57733-4](https://doi.org/10.1016/S0015-0282(16)57733-4)
873 Wishart, D.S., Tzur, D., Knox, C., Eisner, R., Guo, A.C., Young, N., Cheng, D., Jewell, K.,
874 Arndt, D., Sawhney, S., Fung, C., Nikolai, L., Lewis, M., Coutouly, M.-A., Forsythe, I., Tang,
875 P., Shrivastava, S., Jeroncic, K., Stothard, P., Amegbey, G., Block, D., Hau, D.D., Wagner, J.,
876 Miniaci, J., Clements, M., Gebremedhin, M., Guo, N., Zhang, Y., Duggan, G.E., Macinnis,
877 G.D., Weljie, A.M., Dowlatabadi, R., Bamforth, F., Clive, D., Greiner, R., Li, L., Marrie, T.,
878 Sykes, B.D., Vogel, H.J., Querengesser, L., 2007. HMDB: the Human Metabolome Database.
879 *Nucleic Acids Res.* 35, D521-526. <https://doi.org/10.1093/nar/gkl923>
880 Xia, J., Psychogios, N., Young, N., Wishart, D.S., 2009. MetaboAnalyst: a web server for
881 metabolomic data analysis and interpretation. *Nucleic Acids Res.* 37, W652–W660.
882 <https://doi.org/10.1093/nar/gkp356>
883 Xu, B., Guo, N., Zhang, X., Shi, W., Tong, X., Iqbal, F., Liu, Y., 2015. Oocyte quality is
884 decreased in women with minimal or mild endometriosis. *Sci. Rep.* 5, 10779.
885 <https://doi.org/10.1038/srep10779>
886 Yuan, L., Sheng, X., Willson, A.K., Roque, D.R., Stine, J.E., Guo, H., Jones, H.M., Zhou, C.,
887 Bae-Jump, V.L., 2015. Glutamine promotes ovarian cancer cell proliferation through the
888 mTOR/S6 pathway. *Endocr. Relat. Cancer* 22, 577–591. [https://doi.org/10.1530/ERC-15-](https://doi.org/10.1530/ERC-15-0192)
889 0192
890 Zarghami, N., Giai, M., Yu, H., Roagna, R., Ponzzone, R., Katsaros, D., Sismondi, P.,
891 Diamandis, E.P., 1996. Creatine kinase BB isoenzyme levels in tumour cytosols and survival
892 of breast cancer patients. *Br. J. Cancer* 73, 386–390. <https://doi.org/10.1038/bjc.1996.66>
893 Zhou, W.-J., Zhang, J., Yang, H.-L., Wu, K., Xie, F., Wu, J.-N., Wang, Y., Yao, L., Zhuang,
894 Y., Xiang, J.-D., Zhang, A.-J., He, Y.-Y., Li, M.-Q., 2019. Estrogen inhibits autophagy and
895 promotes growth of endometrial cancer by promoting glutamine metabolism. *Cell Commun.*
896 *Signal.* 17, 99. <https://doi.org/10.1186/s12964-019-0412-9>
897 Zondervan, K.T., Cardon, L.R., Kennedy, S.H., 2002. What makes a good case-control study?
898 Design issues for complex traits such as endometriosis. *Hum. Reprod. Oxf. Engl.* 17, 1415–
899 1423. <https://doi.org/10.1093/humrep/17.6.1415>
900
901

902

903

904 **Table 1.** Baseline characteristics of the patients.

| Patient characteristics | Endometriosis | Control | P-value ^d |
|---|---------------|-------------|----------------------|
| | (n = 9) | (n = 7) | |
| Age (years) ^a | 35.7 ± 5.1 | 37.4 ± 3.5 | 0.393 |
| BMI (kg/m ²) ^a | 22.5 ± 3.1 | 23.2 ± 3.7 | 0.606 |
| Parity ^a | 0.1 ± 0.4 | 0.6 ± 0.9 | 0.362 |
| Gravidity ^a | 0.1 ± 0.4 | 0.4 ± 0.8 | 0.407 |
| Infertility | | | 0.771 |
| Primary | 7 (77.8%) | 5 (71.4%) | |
| Secondary | 2 (22.2%) | 2 (28.6%) | |
| Length of infertility (months) ^a | 32.8 ± 11.4 | 34.3 ± 18.6 | 0.679 |
| Day 3 ovarian reserve | | | |
| FSH (IU/mL) ^a | 6.4 ± 3.3 | 6.7 ± 2.9 | 0.957 |
| LH (IU/mL) ^a | 4.3 ± 2.8 | 4.4 ± 1.1 | 0.707 |
| Estradiol (pg/mL) ^a | 86.2 ± 83.5 | 49.1 ± 21.1 | 0.397 |
| AMH (ng/mL) ^a | 2.9 ± 1.6 | 2.9 ± 1.3 | 0.634 |
| Antral Follicular Count ^a | 16.8 ± 9.6 | 20.9 ± 11.3 | 0.457 |
| Surgical classification of endometriosis (n, %) ^b | | | |
| DIE with associated OMA | 5 (55.6%) | NA | NA |
| DIE without associated OMA | 4 (44.4%) | NA | NA |
| Intestinal DIE | 5 (55.5%) | NA | NA |
| Total number of DIE lesions ^a | 2.8 ± 1.1 | NA | NA |
| Follicular volume (mL) | 1.9 ± 0.7 | 1.9 ± 0.8 | 0.874 |
| Oocyte retrieved | 12.6 ± 8.9 | 9.6 ± 6.3 | 0.632 |

905
906 *Note: BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing*
907 *hormone; AMH, anti-Müllerian hormone; OMA, ovarian endometrioma; DIE, deep*
908 *infiltrating endometriosis; NA, not applicable*

909 ^a *The data are presented as means ± the standard deviation*

910 ^b *According to a previously published surgical classification for deep infiltrating*
911 *endometriosis (Chapron et al., 2006)*

912 ^d *The statistical analysis was performed using Fisher's exact test or Pearson's chi-*
913 *square for the qualitative variables and the Mann-Whitney U test for the quantitative*
914 *variables,*

915 *Statistical significance: p < 0.05*

916

917

918 **Table 2.** Baseline characteristics of the OMA+ and the OMA- DIE patients.

| Patient characteristics | OMA+ | OMA- |
|---|-------------|--------------|
| | (n = 5) | (n = 4) |
| Age (years) ^a | 34 ± 1.7 | 37.8 ± 7.4 |
| BMI (kg/m ²) ^a | 22.4 ± 2.6 | 22.6 ± 4 |
| Parity ^a | 0 | 0.25 ± 0.5 |
| Gravidity ^a | 0 | 0 |
| Infertility | | |
| Primary | 4 (80%) | 3 (75%) |
| Secondary | 1 (20%) | 1 (25%) |
| Length of infertility (months) ^a | 28.5 ± 11.4 | 37 ± 11.1 |
| Day 3 ovarian reserve | | |
| FSH (IU/mL) ^a | 6.2 ± 1.1 | 6.8 ± 5.3 |
| LH (IU/mL) ^a | 3.4 ± 3 | 5.5 ± 2.4 |
| Estradiol (pg/mL) ^a | 37.2 ± 21.4 | 147.5 ± 94.8 |
| AMH (ng/mL) ^a | 3.5 ± 2 | 2.1 ± 0.5 |
| Antral Follicular Count ^a | 17.6 ± 9.6 | 15.8 ± 11.1 |
| Follicular Volume (mL) | 1.6 ± 0.4 | 2.4 ± 0.8 |
| Oocyte retrieved | 14 ± 12 | 10.8 ± 3.3 |

919

920

921 *Note: BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing*
 922 *hormone; AMH, anti-Müllerian hormone; OMA, ovarian endometrioma; DIE, deep*
 923 *infiltrating endometriosis; NA, not applicable*

924 ^a *The data are presented as means ± the standard deviation*

925

926

927

928

929

930

931

932 **Figure 1. Representative 500 MHz ¹H-NMR (nuclear magnetic resonance)**
933 **spectrum of a deep infiltrating endometriosis follicular fluid (FF) sample.**

934
935 *Note: TYR, tyrosine; GLN, glutamine; ALA, Alanine; THR, threonine; ILE, isoleucine.*
936 *¹H-NMR spectrum of a follicular fluid sample from a patient with endometriosis,*
937 *obtained at 300 K on a spectrometer operating at a proton frequency of 500.45 MHz.*
938 *The assignment of statistically relevant metabolites is indicated above their*
939 *corresponding NMR peaks.*

940
941
942
943
944
945
946

Figure 2: Endometriosis (n = 50) vs. Control (n = 29): Univariate analysis.

947 The results are presented as boxplots showing statistically significant differences
948 ($p < 0.05$) in metabolite concentrations obtained from the Student's *t*-test using
949 MetaboAnalyst (Chong *et al.*, 2018; Xia *et al.*, 2009).

950 The data are presented as medians, interquartile ranges, and individual values. The
951 average value for each group is also indicated as a yellow diamond.

952 *Note: C, control samples; DIE, deep infiltrating endometriosis samples*

953 **2A.** Boxplots corresponding to glucose, lactate, and pyruvate metabolites.

954 **2B.** Boxplots corresponding to ketone body and lipid metabolites. *Note: FA, fatty*
955 *acids*

956 **2C.** Boxplots corresponding to amino acid, citrate, and creatine metabolites.

957 *Note: TYR, tyrosine; ALA, alanine; THR, threonine; ILE, isoleucine*

958

959
960 **Figure 3: Endometriosis (n = 50) vs. Control (n = 29): Supervised multivariate**
961 **analysis.**

962 The data were obtained using SIMCA software.

963 **3A:** Score plot of the orthogonal partial least square discriminant analysis (OPLS-DA)
964 of the follicular fluid samples. Full and dashed-line circles correspond to the presence
965 and absence of endometrioma, respectively, within the DIE group.

966 The corresponding quality factors were as follows: $R^2X = 0.839$, $R^2Y = 0.844$, and
967 $Q^2 = 0.697$. The OPLS-DA model was validated with a p-value of 6.09×10^{-13} ,
968 obtained using CV-ANOVA.

969 *Note: C, control samples; DIE, deep infiltrating endometriosis*

970

971 **3B.** Variable importance in projection (VIP) score plot for the multivariate analysis of
972 the follicular fluid samples.

973 *Note: THR, threonine; FA, fatty acid*

974 *The variables contributing the most to the group discrimination in the OPLS-DA*
975 *model were plotted according to their VIP score, i.e., the weight of each variable in*
976 *the group separation. The chemical shift center of the corresponding variable NMR*
977 *signal is indicated on the X-axis. The same metabolite can have different NMR*
978 *signals, thus giving rise to different buckets. The variables were sorted according to*
979 *their VIP score, with a threshold of 1 to consider the variables that have a significant*
980 *power on the separation of groups in the OPLS-DA model. The metabolites that*
981 *exhibited increased levels in patients with endometriosis are indicated by a black*
982 *box; those that had reduced levels are indicated by a white box. All of the metabolites*
983 *were also validated in the univariate analysis ($p < 0.05$).*

984

985
986
987
988
989
990
991
992

Figure 4: DIE with endometrioma (OMA+, n = 25) vs. DIE with no endometrioma (OMA-, n = 25) vs. Control (n = 29): Univariate analysis.

993 The results are presented as boxplots showing statistically significant differences in
994 metabolite concentrations obtained from a one-way ANOVA for comparisons
995 between the three groups ($p < 0.05$), whereas the Student's *t*-test was used for the
996 comparison of each combination of pairs (* $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$). The
997 data were obtained using MetaboAnalyst (Chong *et al.*, 2018; Xia *et al.*, 2009).

998 The data are presented as medians, interquartile ranges, and individual values. The
999 average value for each group is also indicated as a yellow diamond.

1000 *Note: C, control samples; OMA-, deep infiltrating endometriosis (DIE) with no*
1001 *endometrioma samples; OMA+, DIE endometriosis with endometrioma samples*

1002 **4A.** Boxplots corresponding to ketone body and glycerol metabolites.

1003 **4B.** Boxplots corresponding to glucose, lactate, and pyruvate metabolites.

1004 **4C.** Boxplots corresponding to amino acids, succinate, and creatine metabolites.

1005 *Note: ILE, isoleucine; TYR, tyrosine, ALA, alanine; THR, threonine; GLN, glutamine*

1006
1007
1008
1009
1010
1011
1012

Figure 5 (in Supplementary files): DIE with endometrioma (OMA+, n = 25) vs. DIE with no endometrioma (OMA-, n = 25) vs. Control (n = 29): Supervised multivariate analysis.

1013 Score plot of the orthogonal partial least square discriminant analysis (OPLS-DA) of
1014 the follicular fluid samples using SIMCA software.

1015 The corresponding quality factors were as follows: $R^2X = 0.87$, $R^2Y = 0.858$, and
1016 $Q^2 = 0.756$.

1017 The OPLS-DA model was validated with a p-value of 1.9×10^{-14} , obtained using CV-
1018 ANOVA.

1019 *Note: C, control samples; OMA-, DIE without associated endometrioma samples;*
1020 *OMA+, DIE with associated endometrioma sample.*

1021

1022

1023 **Figure 6: Schematic representation of the putative metabolic pathways altered**
1024 **in the follicular fluid from patients with endometriosis.**

1025

1026


1027 *Note: FA, fatty acids; KB, ketone bodies; P-Creatine, phosphocreatine; ROS, reactive*
1028 *oxygen species; TCA, tricarboxylic acid cycle*

1029 *Large grey arrows indicate the variation in metabolite concentrations in the follicular*
1030 *fluid (FF) from patients with DIE compared with their concentration in control*
1031 *samples.*

1032 A dysfunctional TCA cycle could explain the observed accumulation of threonine
1033 observed in the DIE FF samples. Citrate, which would no longer be used in this
1034 pathway, can be converted into oxaloacetate in the cytoplasm, thereby giving rise to
1035 reactive oxygen species (ROS) as well as an inflammatory response.

1036 In the FF of endometriosis patients with no endometrioma, glucose is directed toward
1037 pyruvate and lactate production by the anaerobic glycolysis pathway (blue).
1038 Conversely, the presence of an endometrioma is characterized by a predilection
1039 toward other energetic pathways, such as lipolysis followed by fatty acid β -oxidation,
1040 thereby resulting in the release of glycerol and ketone bodies (red).


1 **Figure 1.**



26 **Figure 2**

27


2A



28

29


2B



30

31

2C



32


33 *p-value < 0.05

34 **p-value < 0.01

35 ***p-value < 0.001


36

37 **Figure 3**



38

39



40

41 **Figure 4**


42

43

44

45

46




4B

Glucose

Lactate

Pyruvate



47

48

49


50

51

52

53

54



55


56

57

58


59

60 **Figure 5**
61
62



63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91

92 **Figure 6**
 93
 94



95
 96
 97
 98
 99